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Implication for health policy/practice/research/medical education:
Inflammatory markers can be considered as risk factors for the development of metabolic syndrome in obese subjects. The present study 
confirms the role of hs-CRP as an inflammatory marker in the progression of metabolic syndrome in obese patients and its association 
with vitamin D deficiency that can play a significant role in prevention and control of metabolic syndrome in obese individuals.
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Introduction: Serum level of high sensitivity C-reactive protein (hs-CRP), as an inflammatory 
marker, can play a role in development of metabolic syndrome in obese individuals. 
Objectives: This study aimed to determine serum concentration of hs-CRP in obese patients 
with metabolic syndrome and determine the association of this factor with factors involved in the 
progression of metabolic syndrome.
Patients and Methods: In this study, samples were selected by convenient method from obese 
patients, admitted to Kashani and Hajar hospitals (Shahrekord, Iran). First, based on NCEP-ATPIII-
defined metabolic syndrome, parameters of metabolic syndrome and serum levels of vitamin D 
were measured and a questionnaire containing demographics was completed for each participant. 
Accordingly, the samples (n=192) were divided into two identical groups; obese individuals without 
metabolic syndrome (controls) and obese individuals with metabolic syndrome (case group). Hs-
CRP levels were measured in both groups. 
Results: Serum level of hs-CRP in the case group was 17.58±1.40 µg/mL and in the control group 
was 9.04±1.26 µg/mL, which was significantly higher in the case group than the control group 
(P < 0.001). Serum concentration of hs-CRP in case and control subjects had a negative significant 
correlation with vitamin D (P <0.001), however, serum level of hs-CRP had no significant 
association with high density lipoprotein cholesterol (HDL-C), triglyceride (TG), fasting blood 
sugar (FBS), abdominal circumference, body mass index (BMI), and height (P > 0.05).
Conclusion: Hs-CRP can be used for prognosis and early detection of patients at risk of metabolic 
syndrome. 
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Introduction 
Metabolic syndrome is a serious complication that 
develops following a sedentary lifestyle and poor 
nutrition. This syndrome was first introduced in 
1998 as one of the background factors contributing 
to cardiovascular diseases and diabetes (1) and is also 
known by other names, including syndrome X, insulin 
resistance syndrome, deadly quartet, obesity-dyslipidemia 
syndrome, and Reaven’s syndrome (2). The prevalence 
of metabolic syndrome is different due to differences 
in age and race of the studied population and the 
diagnostic criteria used in different parts of the world. 
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However, increased urbanization, lack of mobility, stress, 
and consumption of fatty foods, high carbohydrates, 
and high calories caused a consistent increased rate of 
metabolic syndrome over the past 20 years all over the 
world. According to the recent researches, it involves up 
to 25% of the general population (3,4). This syndrome 
includes a number of clinical findings and laboratory 
abnormalities, such as obesity (central, abdominal or 
visceral), increased activity of the sympathetic nervous 
system, hypertension, glucose intolerance, insulin 
resistance, compensatory hyperinsulinemia, type 2 
diabetes, dyslipidemia (hypertriglyceridemia, elevated 
low or high density lipoprotein cholesterol [HDL-C]), 
fatty liver, impaired fibrinolysis, hyperuricemia, systemic 
inflammation, especially endothelial dysfunction and 
vascular inflammation (5). As defined by NCEP ATP-III 
(1), metabolic syndrome is diagnosed with at least 3 risk 
factors, including obesity, hypertriglyceridemia, low HDL 
cholesterol, hypertension, and hyperglycemia. However, 
identification of other causes of this syndrome can play 
an important role in awareness and early detection of this 
syndrome and its treatment control. 
Objectives
In this regard, the study aimed to measure the serum 
concentration levels of high sensitivity C-reactive protein 
(hsCRP), as an inflammatory marker in obese patients 
without metabolic syndrome and the association between 
these factors and other metabolic factors involved in the 
development of metabolic syndrome. 
Patients and Methods
Study population
This cross-sectional study was conducted during 2016-
2017 on patients admitted to Hajar and Kashani hospitals, 
eligible for inclusion, comprising of body mass index 
(BMI) ≥25 kg/m2, age >18, and metabolic syndrome 
parameters. The exclusion criteria for this study consisted 
of having kidney or liver disease, using weight loss drugs, 
or other weight reduction interventions, using vitamin 
D supplements, being pregnant or breast-feeding, taking 
estrogen and progesterone pills in women and withdraw 
to continue the study, laboratory tests, or examinations. 
Sampling was based on convenient method. A total of 
192 patients were selected based on inclusion/exclusion 
criteria and were considered as sample size. Serum lipids 
levels (HDL-C, LDL-C, and triglyceride [TG]) and Fasting 
blood sugar (FBS) of all patients were determined in 
venous blood samples and sent to the laboratory. Metabolic 
syndrome was defined based on NCEP ATP-III criteria. 
After identifying patients with metabolic syndrome, 
patients were divided into two groups; 96 patients (those 
with the metabolic syndrome and obesity) and 96 obese 
individuals (those with obesity and without the metabolic 
syndrome). The two groups were selected based on similar 
gender, age, occupation, physical activity, smoking, type of 
urban and rural population and educational level. In this 
study, vitamin D and hs-CRP levels were measured and 
the association between hs-CRP and metabolic syndrome 
parameters was determined in obese subjects. 
Ethical issues
1) The research followed the tenets of the Declaration 
of Helsinki; 2) informed consent was obtained; and 3) 
This study was approved by the Ethics Committee of 
Shahrekord University of Medical Sciences (ethical code# 
IRSKUMS.REC.1395.247). 
Statistical analysis
Data were entered into an Excel database and then analyzed 
using the SPSS software version 22, using descriptive and 
inferential statistics, such as mean and standard deviation 
(SD), as well as t test, chi-square and Pearson’s correlation 
coefficients and P < 0.05 was considered significant.
Results 
A total of 192 patients participated in this study with 
mean age of 51.37 ± 19.82 years, who were divided into 
two groups, after synchronization. The mean age of 
patients in the case group was 50.09 ± 1.94 years and in 
the control group was 52.57 ± 2.05 years. There was no 
significant difference between the two groups in terms of 
height, weight, BMI, systolic hypertension, and abdominal 
circumference (P < 0.05). 
Mean of serum level of hs-CRP in the case group was 
17.58 ± 1.40 µg/mL and in the control group was 9.04 ± 1.26 
µg/mL, which was significantly higher in the case group 
than the control group (P < 0.001) with a maximum level 
of hs-CRP at 36.4 µg/mL and minimum at 0.1 µg/mL. 
The distribution of hs-CRP in the groups is presented in 
Table 1.
Serum level of hs-CRP was inversely associated with 
vitamin D in case (r=-0.32) and control (r=-0.34) subjects, 
based on Pearson’s correlation coefficient (P < 0.001). 
Also hs-CRP was significantly associated with weight 
in the control group (r=-0.31; P < 0.001), but there was 
no significant association in the case group (P > 0.05). 
Serum level of hs-CRP had no significant association 
with HDL-C, TG, FBS, abdominal circumference, BMI, 
and height in the groups, based on Pearson’s correlation 
coefficient (P > 0.05, Table 2).
Discussion 
This study aimed to determine serum concentration of hs-
CRP in obese patients without metabolic syndrome and its 
association with metabolic syndrome parameters. Serum 
concentration of hs-CRP was significantly higher in 
patients than the control group and there was a significant 
negative correlation between serum levels of vitamin D 
and hs-CRP. However, association of serum concentration 
of hs-CRP and other markers of metabolic syndrome was 
not statistically significant. 
In the present study, serum levels of hs-CRP increased 
with decreased serum levels of vitamin D and since 
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decreased vitamin D increases the serum levels of TG, BP, 
and FBS and reduces HDL-C and all these variables are 
effective in the incidence of cardiovascular diseases, it can 
be justified that decreased vitamin D increases the serum 
levels of hs-CRP and risk of cardiovascular diseases in 
patients with metabolic syndrome. In a study conducted 
by Salek-Zamani et al in 2011, no significant difference 
in serum levels of vitamin D and PTH between the group 
with metabolic syndrome and the control group was 
detected, but a significant difference in hs-CRP levels and 
insulin resistance (6) was seen among them. Additionally, 
Tamakoshi et al showed that many of the metabolic 
syndrome parameters have a significant association with 
increased levels of hs-CRP (7). The association between 
concentrations of inflammatory markers and metabolic 
syndrome and body mass index in 80 patients with 
metabolic syndrome and 160 healthy individuals showed 
an increased concentration of hs-CRP in patients and is 
directly associated in women with increased body mass 
index and in men with waist circumference (8). Zarkesh et 
al in a cross-sectional study found that the concentration of 
three inflammatory markers is associated with metabolic 
syndrome on a population of 365 adults who participated 
in Tehran lipid and glucose study and reported increased 
hs-CRP levels associated with metabolic risk factors (9). 
In another study by Majd et al in 2016 on the association 
between serum hs-CRP and metabolic syndrome, the 
results showed that the levels of this protein increased 
significantly in patients with metabolic syndrome, 
compared to the control group (10). 
Totally, different studies showed the association between 
inflammation and metabolic syndrome. However, 
the causal relationship between inflammation and 
metabolic syndrome and mechanism of this association 
is of great importance. Recent studies presented that 
in the process of developing metabolic syndrome, 
white fat increases, permeability of cells increases, and 
there is an imbalance between pro-inflammatory and 
anti-inflammatory cytokines. Macrophage infiltration 
in adipose tissue provides a source of inflammatory 
signals, while fat tissue interferes in its metabolism and 
controls metabolic changes associated with obesity (11). 
Inflammatory signals or cytokines increase the expression 
of superficial molecules involved in inflammation on the 
endothelial cells, smooth muscle cells, and macrophages 
and triggers inflammation by some reactions that present 
as inflammation markers of hs-CRP. Overall, metabolic 
syndrome is a pre- inflammatory condition and adipose 
tissue leads to increased inflammation in individuals (12). 
Conclusion 
We concluded that decreased serum levels of vitamin 
D and increased serum levels of hs-CRP in patients 
with metabolic syndrome are inflammatory-dependent 
processes that can lead to various risks, including 
cardiovascular diseases and diabetes. Therefore, hs-CRP 
can be used in early diagnosis and screening patients at 
risk of developing metabolic syndrome, especially in high-
risk individuals.
Limitations of the study
One of the limitations of the present study was that patients 
who were affected by cardiovascular and renal diseases or 
those needed hospitalization during the research were 
excluded from the study. The collaboration tendency of 
subjects hospitalized at Kashani and Hajar hospitals was 
another limitation. 
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Table 1. Distribution of the frequency of hs-CRP levels in the study groups
hs-CRP
Groups
Patients with metabolic syndrome Control (obese individuals without metabolic syndrome) Total
Low risk (<1.0 µg/mL) 10 (10.41%) 32 (33.33%) 42 (21.78%)
Normal (1-3 µg/mL) 12 (12.50%) 21 (21.87%) 33 (17.18%)
High risk (>3.0 µg/mL) 74 (77.08%) 43 (44.79%) 117 (60.93)
Total 96 (100) 96 (100) 192 (100)
Table 2. Association of hs-CRP with vitamin D and metabolic syndrome parameters
Groups
Variables
BMI (kg/m2) FBS (mg/dL) TG (mg/dL) HDL-C (mg/dL) Vitamin D (ng/dL)
Patients with metabolic syndrome 
(n=96)
Pearson’s correlation 
coefficient
0.03 0.08 0.16 0.18 -0.32
P value 0.77 0.43 0.10 0.06 <0.001
Control (obese individuals without 
metabolic syndrome; n=96)
Pearson’s correlation 
coefficient
0.16 0.01 0.09 0.11 -0.34
P value 0.09 0.85 0.34 0.24 <0.001
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